GPRC5D Full-Length Membrane Proteins, Antibodies and Stable Cell Lines

G-protein coupled receptor class C group 5 member D (GPRC5D) is an orphan class C G protein-coupled receptor with a seven-transmembrane architecture. Unlike many broadly expressed GPCRs, GPRC5D shows relatively restricted expression in normal tissues, with notable expression in hair-follicle-associated structures, while high cell-surface expression is observed on malignant plasma cells in multiple myeloma. Its expression is largely independent of BCMA, making GPRC5D particularly valuable as a complementary target in plasma-cell malignancy research. Although its endogenous ligand and complete signaling biology remain incompletely understood, its accessible cell-surface expression has driven development across antibody, T-cell engager, ADC, and engineered cell-therapy formats. Explore the latest progress of GPRC5D-targeted drug…

Because GPRC5D is a multi-pass GPCR, preservation of native membrane conformation is critical for antibody discovery. DIMA BIOTECH offers a broad panel of full-length GPRC5D proteins in MNP, Nanodisc, and cell-free membrane formats, together with recombinant extracellular-domain proteins. These reagents support native-conformation antibody screening, SPR/BLI, binding characterization, and specificity assessment. The portfolio also includes monoclonal antibodies, biosimilar reference antibodies, PE/biotin conjugates, and a GPRC5D-overexpressing K562 stable cell line for ELISA, flow cytometry, FACS, and cell-binding studies. In addition, to accelerate the development of GPRC5D biotherapy, DIMA BIOTECH has also prepared a GPRC5D target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple GPRC5D IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.

Can’t find the right product? Please fill up the following form and let us know your special needs. We will get back to you shortly with our solutions.





    Please prove you are human by selecting the truck.

    We have various technologies for antibody-based drug development. Here is a summary of our platforms:

    1. DiMProTM membrane protein platform: Use mammalian cells to express and purify membrane proteins. We have over 1000 on-shelf functional proteins, out of which, 50+ are active full-length multi-pass membrane proteins. For multi-pass transmembrane proteins, such as GPCRs and ion channels, we have five different solutions, i.e., Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Nanodisc.

    2. DimAb® single B-cell antibody discovery platform: Our DimAb® B cell library can help customers easily obtain over 10,000 positive hits in as short as a month’s time.

    3. DiLibraryTM mammalian display antibody engineering platform: A proprietary platform works great for antibody humanization, affinity maturation and other engineering applications. The developability of Ab molecules engineered from this system is much better than Abs from phage or yeast display platforms.